These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 18369825)
1. Telomerase inhibition combined with other chemotherapeutic reagents to enhance anti-cancer effect. Tauchi T; Ohyashiki JH; Ohyashiki K Methods Mol Biol; 2007; 405():181-9. PubMed ID: 18369825 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Tauchi T; Nakajima A; Sashida G; Shimamoto T; Ohyashiki JH; Abe K; Yamamoto K; Ohyashiki K Clin Cancer Res; 2002 Nov; 8(11):3341-7. PubMed ID: 12429620 [TBL] [Abstract][Full Text] [Related]
3. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Tauchi T; Shin-ya K; Sashida G; Sumi M; Okabe S; Ohyashiki JH; Ohyashiki K Oncogene; 2006 Sep; 25(42):5719-25. PubMed ID: 16652154 [TBL] [Abstract][Full Text] [Related]
4. Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Tauchi T; Shin-Ya K; Sashida G; Sumi M; Nakajima A; Shimamoto T; Ohyashiki JH; Ohyashiki K Oncogene; 2003 Aug; 22(34):5338-47. PubMed ID: 12917635 [TBL] [Abstract][Full Text] [Related]
5. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia. Sumi M; Tauchi T; Sashida G; Nakajima A; Gotoh A; Shin-Ya K; Ohyashiki JH; Ohyashiki K Int J Oncol; 2004 Jun; 24(6):1481-7. PubMed ID: 15138591 [TBL] [Abstract][Full Text] [Related]
6. STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis. Jakubowska J; Wasowska-Lukawska M; Czyz M Eur J Pharmacol; 2008 Oct; 596(1-3):41-9. PubMed ID: 18782571 [TBL] [Abstract][Full Text] [Related]
7. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells. Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913 [TBL] [Abstract][Full Text] [Related]
8. Imatinib resistance in multidrug-resistant K562 human leukemic cells. Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528 [TBL] [Abstract][Full Text] [Related]
9. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP. Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346 [TBL] [Abstract][Full Text] [Related]
10. Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Lee KH; Rudolph KL; Ju YJ; Greenberg RA; Cannizzaro L; Chin L; Weiler SR; DePinho RA Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3381-6. PubMed ID: 11248087 [TBL] [Abstract][Full Text] [Related]
11. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells. Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579 [TBL] [Abstract][Full Text] [Related]
12. Telomerase as a target for cancer therapy. Parkinson KE Curr Opin Investig Drugs; 2005 Jun; 6(6):605-10. PubMed ID: 15988912 [TBL] [Abstract][Full Text] [Related]
13. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Kurosu T; Ohki M; Wu N; Kagechika H; Miura O Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover. Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551 [TBL] [Abstract][Full Text] [Related]
15. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells. Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435 [TBL] [Abstract][Full Text] [Related]
16. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Kominsky DJ; Klawitter J; Brown JL; Boros LG; Melo JV; Eckhardt SG; Serkova NJ Clin Cancer Res; 2009 May; 15(10):3442-50. PubMed ID: 19401345 [TBL] [Abstract][Full Text] [Related]